Renal Transplant
Conditions
Brief summary
The purpose of the study is to determine a) if the implementation of belatacept patient alert card (PAC) resulted in effective understanding of key safety messages and b) if the degree of understanding of key safety messages is associated with improved clinical and safety outcomes.
Detailed description
3 sub studies: 2 Cross-Sectional and 1 retrospective chart review
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient survey (cohort 1): * Patients has taken belatacept within the previous 3 months for renal transplantation * Patient is over 18 years of age * HCP survey (cohort 2): * Physician or nurses working in nephrology centers, with at least 1 patient taking belatacept in the previous 6 months for renal transplantation (by prescribing, administering or by follow up) * Retrospective chart review study (cohort 3): * Patient survey questionnaire received, Informed Consent Form (ICF) signed (if required)
Exclusion criteria
* Patient survey: * Patient has participated in a clinical trial for their renal condition in the previous 12 months * Currently an employee of BMS * HCP survey: * Physicians or nurse who have recruited patients for the Patient survey * Currently an employee of BMS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Retrospective chart review study (clinical outcome study): Proportion of serious infections | Upto 4 years | — |
| Patient survey: Mean scores for correct responses for questions grouped by objectives | At patient enrolment | Objectives: distribution, awareness, utility, utilization and knowledge |
| HCP survey: Proportion of HCPs who prescribe or administer belatacept in nephrology centres who are aware of the PAC | Day 1 | — |
| HCP survey: Proportion of HCPs who have utilised the PAC, and the extent of its use | Day 1 | — |
| HCP survey: Levels of HCPs' knowledge and comprehension related to the important identified risks of infections and the need to screen for specific infection prior to initiating or administering belatacept | Day 1 | The percentage of HCPs with responses to each question in the HCP questionnaire that would indicate effectiveness of the PAC will be determined: who are aware of the PAC, use the PAC, level of knowledge and comprehension of the risks and mean scores for correct responses |
| HCP survey: Behavior of HCPs based on responses to behavioral questions | Day 1 | — |
| HCP survey: Mean total score for correct responses | Day 1 | — |
| HCP survey: Mean scores for correct responses for questions grouped by objectives | Day 1 | Objectives: distribution, awareness, utility, utilization and knowledge |
| Patient survey: Proportion of patients treated with belatacept who are aware of the existence of the PAC | At patient enrolment | — |
| Patient survey : Proportion of patients treated with belatacept who have received the PAC | At patient enrolment | — |
| Patient survey : Proportion of patients who have utilised the PAC, and the extent of its use | At patient enrolment | — |
| Patient survey: Levels of patient knowledge and comprehension related to the important identified risks of belatacept treatment | At patient enrolment | — |
| Patient survey: HCP-patient communication based on responses to specific questions | At patient enrolment | — |
| Patient survey: Proportion of patients with correct responses to behavioral questions | At patient enrolment | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major determinants of understanding the key messages contained in the PAC based on data collected in the patient questionnaire | At patient enrolment | Determinants: Age, gender, educational level, number of prescription medications, duration of therapy with belatacept |
| Major determinants of implementation regarding the key messages contained in the PAC based on data collected in the patient questionnaire | At patient enrolment | Determinants: Age, gender, educational level, number of prescription medications, duration of therapy with belatacept |
| Determinants of Health Care Professional (HCP) understanding and implementation regarding key messages contained in the PAC based on data collected in the patient questionnaire | Day 1 | Determinants: type of HCP, country, age and gender of HCP years in specialty, number of HCPs in the unit, annual number of patients through the unit, number of patients for whom belatacept was prescribed in the previous 12 months, type of practice, type of institution (academic or non-academic), size of town |
| Retrospective chart review study (clinical outcome study) : proportion of infections leading to discontinuation | Upto 4 years | — |
| Retrospective chart review study (clinical outcome study) : mean time from symptom onset of infection to receipt of medical therapy | Upto 4 years | — |
| Retrospective chart review study (clinical outcome study) : Mean time to diagnosis of graft rejection by biopsy criteria | Upto 4 years | — |
| Major determinants of patients knowledge of the key messages contained in the belatacept PAC based on data collected in the patient questionnaire | At patient enrolment | Determinants: Age, gender, educational level, number of prescription medications, duration of therapy with belatacept |
Countries
Austria, France, Germany, Sweden
Outcome results
None listed